Tocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis.
نویسندگان
چکیده
The Giant Cell Arteritis Actemra (GiACTA) study, the largest randomised trial for this disease to date, involved 251 patients and describes the benefits of tocilizumab, an interleukin-6 inhibitor.1 Patients were randomised to one of 4 groups, in a ratio of 2:1:1:1, to receive: subcutaneous tocilizumab 162 mg weekly (100 patients); or every 2 weeks (50 patients); or placebo (one arm of 50 patients and another of 51). In 3 arms of the study, all patients were subject to protocol defi ned prednisolone tapered over 26 weeks, such that prednisolone was discontinued by week 26 and replaced with placebo. In one of the placebo arms prednisolone taper was extended over 52 weeks, achieving a prednisolone dose of 7 mg at 26 weeks followed by reductions of 1 mg every month thereafter.2 Prednisolone doses in a range of 20 to 60 mg were permitted at enrolment and tapering was based on that enrolment dose. When a dose below 20 mg was achieved, numbered blistered packs were provided to allow blinded steroid administration. The study was funded by Hoffmann-La Roche. Ten of the 16 listed authors disclosed confl icts of interest in relation to Roche.
منابع مشابه
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinica...
متن کاملFor Biologics in Vasculitis, Decidedly Mixed Results
Most of the current evidence for biologics to treat systematic vasculitis (SV) doesn’t come from randomized clinical trials, but from uncontrolled, observational studies – which show mixed results in producing and sustaining remission, according to a new literature review. In the 90 studies analyzed, rituximab (Rituxan) was the biological most often used in ANCA-associated vasculitis (AAV), fol...
متن کاملInterleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis.
متن کامل
Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti-Interleukin-6 Receptor Antibody
Giant cell arteritis (GCA) is the most common form of systemic vasculitis in adults, affecting preferentially medium-large size arteries. Here we report a case of a female with a diagnosis of GCA based on temporal artery biopsy, successfully treated with tocilizumab, a humanized anti-interleukin-6 receptor antibody.
متن کاملA Case of Temporal Artery Dissection in a Patient with Giant Cell Arteritis
Giant cell arteritis (GCA) is a chronic vasculitis involving medium and large sized arteries. A 73-year-old male presented with right eye visual loss and jaw claudication associated with photosensitivity, supraorbital and retrobulbar pain. Evaluation demonstrated bitemporal tenderness, elevated ESR, CRP, leukocytosis and positive PANCA. Stranding and abnormal enhancement of right retrobulbar fa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The journal of the Royal College of Physicians of Edinburgh
دوره 47 3 شماره
صفحات -
تاریخ انتشار 2017